0001437749-16-028526.txt : 20160328
0001437749-16-028526.hdr.sgml : 20160328
20160328210431
ACCESSION NUMBER: 0001437749-16-028526
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20160324
FILED AS OF DATE: 20160328
DATE AS OF CHANGE: 20160328
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: RESPONSE BIOMEDICAL CORP
CENTRAL INDEX KEY: 0000806888
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-TESTING LABORATORIES [8734]
IRS NUMBER: 000000000
STATE OF INCORPORATION: A1
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1781 - 75TH AVENUE W.
CITY: VANCOUVER
STATE: A1
ZIP: V6P6P2
BUSINESS PHONE: 604-456-6010
MAIL ADDRESS:
STREET 1: 1781 - 75TH AVENUE W.
CITY: VANCOUVER
STATE: A1
ZIP: V6P6P2
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Shuster Lewis
CENTRAL INDEX KEY: 0001471131
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-50571
FILM NUMBER: 161533433
MAIL ADDRESS:
STREET 1: 421 BRIDOON TERRACE
CITY: ENCINITAS
STATE: CA
ZIP: 92024
4
1
rdgdoc.xml
FORM 4
X0306
4
2016-03-24
0000806888
RESPONSE BIOMEDICAL CORP
RBM
0001471131
Shuster Lewis
1781 - 75TH AVENUE W.
VANCOUVER
A1
V6P 6P2
BRITISH COLUMBIA, CANADA
1
Deferred Share Unit Award (Right to Receive)
0
2016-03-24
4
A
0
36764
0
A
Common Stock
36764
36764
D
Stock Option (right to buy)
0.85
2016-03-24
4
A
0
5000
0
A
2026-03-23
Common Stock
5000
5000
D
Reporting person has received an exempt award of Deferred Share Units ("DSUs") under the Issuer's Non-Employee Directors Deferred Share Unit Plan (the "Plan"). DSUs represent a right to receive shares of the issuer's common stock (or, in the sole discretion of the Issuer's Board of Directors following a Change in Control as defined in the Plan, cash, securities or a combination of cash and securities equal to the fair market value thereof) upon the reporting person's termination of service for the issuer. The DSUs are immediately vested and expire 90-days following the reporting person's Termination Date as defined in the Plan.
Exercise prices shown are denominated in Canadian dollars.
Subject to the reporting person's continued service as a director of the company through each vesting date, 100% of the shares subject to the option shall vest and become exercisable on March 24, 2017.
/s/ Anastasios Tsonis, Attorney-in-Fact
2016-03-28